Shots: Janssen to present new data from the fixed-duration cohort of P-II CAPTIVATE study, demonstrating 95% of patients treated with combined Imbruvica + Venetoclax were alive and progression-free @2yrs. with deep remissions were seen across all subgroups, including patients with high-risk CLL Additionally, Janssen will present 7yrs. data from the RESONATE-2 study on PFS and […]Read More
Shots: The P-I/II study involves assessing Mobocertinib (160mg, PO) in patients with EGFR Exon20 insertion+ mNSCLC who received prior Pt-based CT The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over 1yr of follow up and will be presented at the ASCO. The updated results demonstrated an encouraging ORR (28%), DoR (17.5mos.), OS […]Read More
The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased […]Read More
Shots: The P-II OPTIC study involves assessing three initial doses of Iclusig (15/30/45 mg) in 283 patients with CML in CF, or who had documented history of the presence of the T315I mutation after receiving any number of previous TKIs With an average follow-up of~ 21 mos., the interim analysis showed that maximum BCR- ABL1 […]Read More
Shots: The P-Ib/II CARTITUDE-1 study involves assessing JNJ-4528 in 29 heavily pretreated patients with r/r MM. The P-Ib results will be shared at ASCO The P-Ib/II study results: 100% ORR with 97% good PR and 3% PR; patients achieving stringent CR @median of 11.5mos (86%), PFS at 9mos (86%); median time to first response was […]Read More
Shots::stohShots: The P-II CITYSCAPE study involves assessing of tiragolumab+ Tecentriq (atezolizumab) vs Tecentriq + PBO to in 135 patients with 1L PD-L1-positive NSCLC. The full results of the study will be presented at ASCO20 Virtual Scientific Program The P-II study results: met its co-1EPs in IIT population, ORR (31.3% vs16.2%), mPFS (5.4 vs 3.6mos.), @exploratory […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
